|
Licensing, Collaborative and Other Arrangements (Details) (USD $)
In Millions, unless otherwise specified |
6 Months Ended |
|---|---|
|
Jun. 30, 2012
|
|
|
Development Milestone [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |
| Amount due upon achievement of milestone | $ 8.5 |
|
Sales Milestone [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |
| Amount due upon achievement of milestone | 15.1 |
|
Collaborative Arrangement [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |
| Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier | 3 |
| Number of patients to be enrolled in trial | 816 |
| License fees paid | $ 1.5 |
| X | ||||||||||
|
- Definition
Amount of potential cash payments that could result from the contingent consideration arrangement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount paid to a licensor for license fee during the period. No definition available.
|
| X | ||||||||||
|
- Definition
The number of fixed-dose combination ("FDC") product candidates included in a portfolio of antihypertensive products from Servier. No definition available.
|
| X | ||||||||||
|
- Definition
The number of patients expected to be enrolled in the clinical trial. No definition available.
|